[Federal Register Volume 85, Number 90 (Friday, May 8, 2020)]
[Notices]
[Pages 27423-27424]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-09924]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Cutting-Edge Basic Research Awards (CEBRA) (R21).
    Date: June 1-5, 2020.
    Time: 8:00 a.m. to 8:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neurosciences Center 
Building, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual 
Meeting).
    Contact Person: Susan O. McGuire, Ph.D., Scientific Review 
Officer, Office of Extramural Affairs, National Institute on Drug 
Abuse, NIH, 6001 Executive Boulevard, Room 4245, Rockville, MD 
20852, (301) 435-1426, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Assessing the Effects of Cannabinoids on HIV-Induced 
Inflammation (R01 Clinical Trial Optional).
    Date: June 10, 2020.
    Time: 11:30 a.m. to 2:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neurosciences Center 
Building, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone 
Conference Call).
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, 
Office of Extramural Affairs, Division of Extramural Research, 
National Institute on Drug Abuse, NIH, 6001 Executive Boulevard, 
Room 4238, MSC 9550, Bethesda, MD 20892, (301) 402-6020, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; NIH Pathway to Independence Award (K99/R00).
    Date: June 15, 2020.
    Time: 1:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neurosciences Center 
Building, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone 
Conference Call).

[[Page 27424]]

    Contact Person: Susan O. McGuire, Ph.D., Scientific Review 
Officer, Office of Extramural Affairs, National Institute on Drug 
Abuse, NIH, 6001 Executive Boulevard, Room 4245, Rockville, MD 
20852, (301) 435-1426, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; SEP III: Step Up for Substance Use Disorders (SUD): 
A Drug Target Initiative for Scientists Engaged in Fundamental 
Research (U18--Clinical Trial Not Allowed).
    Date: June 16, 2020.
    Time: 9:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neurosciences Center 
Building, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone 
Conference Call).
    Contact Person: Sindhu Kizhakke Madathil, Ph.D., Scientific 
Review Officer, Division of Extramural Research, Scientific Review 
Branch, National Institute on Drug Abuse, NIH, 6001 Executive 
Boulevard, Bethesda, MD 20852, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: May 4, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-09924 Filed 5-7-20; 8:45 am]
 BILLING CODE 4140-01-P